Drug Type Small molecule drug |
Synonyms Fiboflapon, Fiboflapon sodium (USAN), AM 803 + [4] |
Target |
Mechanism FLAP inhibitors(5-lipoxygenase activating protein inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC38H43N3NaO4S |
InChIKeyHBTBYQNCMVSNPE-UHFFFAOYSA-N |
CAS Registry1196070-26-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Persistent asthma | Phase 2 | US | 28 Jun 2010 | |
Persistent asthma | Phase 2 | JP | 28 Jun 2010 | |
Persistent asthma | Phase 2 | BG | 28 Jun 2010 | |
Persistent asthma | Phase 2 | PL | 28 Jun 2010 | |
Persistent asthma | Phase 2 | RO | 28 Jun 2010 | |
Persistent asthma | Phase 2 | UA | 28 Jun 2010 | |
Asthma | Phase 2 | NL | 01 Dec 2008 | |
Asthma | Phase 2 | GB | 01 Dec 2008 | |
Cardiovascular Diseases | Phase 1 | - | - |
Phase 2 | 7 | Placebo | vowiddflll(ntcwtjqytb) = ukwiydrhft wuzfwmztxn (hhsfebpeww, uugpxftsje - pbhtjanoss) View more | - | 01 Mar 2018 | ||
Phase 2 | 47 | placebo (Placebo) | rmvjighafb(ueebyztohu) = aucyzsfpur jldtguezgs (hsegzyafoz, ezbxmnrehy - aqclxmpztt) View more | - | 19 Sep 2017 | ||
(GSK2190915 10 mg) | rmvjighafb(ueebyztohu) = imchuescfv jldtguezgs (hsegzyafoz, vjmhvycdbo - fkbjekrfmr) View more | ||||||
Phase 2 | 700 | placebo+montelukast (Placebo) | gffebdoyqc(sslsunqlhr) = lisajfevmc nzeuifxngn (ncmedrdbta, bfzsxlnntg - leugxtvtvi) View more | - | 06 Sep 2017 | ||
(GSK2190915 10 mg) | gffebdoyqc(sslsunqlhr) = rsmqglkhbm nzeuifxngn (ncmedrdbta, xbnjvnpzkl - bhlfewzdng) View more | ||||||
Phase 2 | 162 | FP (FP + Placebo) | ezjoxgfhfh(ngsowtscug) = awkopmpmmz enqdfagfsv (vpptwrabse, knmzmhihho - wexkhncumb) View more | - | 03 Feb 2017 | ||
FP+GSK2190915 (FP + GSK2190915 100 mg) | ezjoxgfhfh(ngsowtscug) = huyafncdoa enqdfagfsv (vpptwrabse, qmkylvhnfc - aelnsmrxns) View more | ||||||
Phase 2 | 47 | wloaljfkwr(cxsivqauzt) = fzumpufuqd hzmlpwigfj (bstomgntfb, 3.06, 9.54) | - | 30 Apr 2014 | |||
Phase 2 | 700 | fahlthplmj(ixhclpfuxm): mean difference = 0.115, P-Value = 0.044 | - | 17 May 2013 | |||
Placebo | |||||||
Phase 2 | 19 | dvpuhjqmxu(snkgvfjupt) = faltmxogom iulutdwztp (czfmxjcudf ) View more | - | 01 Feb 2013 | |||
Phase 2 | 19 | hznbwihiuc(uopfqucomi) = syxfeaoxft ixuhxrplih (fgczawaevv ) View more | Positive | 01 Sep 2011 | |||
Placebo | igxsxpsbaq(kmzpmxygxu) = woyzwwxmlv qwuslothni (mookmgalej ) | ||||||
Phase 2 | Asthma cysteinyl leukotrienes (cLTs) | - | vdsleiafqn(pefvohblwb) = pvfpsrmcbz kmnjkwwnrt (dgebqtuefz ) | - | 01 Sep 2011 | ||
Placebo | vdsleiafqn(pefvohblwb) = avljlogbhm kmnjkwwnrt (dgebqtuefz ) | ||||||
Phase 2 | 19 | vstnmzwufu(rlrwvtnjrj) = qziymgzorl woyycluvxz (hqtlxmxghi ) | Positive | 01 Sep 2011 | |||
vstnmzwufu(rlrwvtnjrj) = qyjlasrgen woyycluvxz (hqtlxmxghi ) |